24/7 Market News Snapshot 30 July, 2025 – Imunon, Inc. Common Stock (NASDAQ:IMNN)

July 30, 2025

DENVER, Colo., 30 July, 2025 (www.247marketnews.com) – (Nasdaq:IMNN) are discussed in this article.
IMUNON, Inc. (Nasdaq:IMNN) is experiencing remarkable momentum in pre-market trading with its stock price reaching $8.727, marking an impressive 11.17% increase from the previous close of $7.850. This surge is accompanied by a trading volume of 1.02 million shares, highlighting significant investor interest as the stock appears to break through key resistance levels. Such technical indicators suggest the potential for continued gains, prompting traders to monitor volume consistency and support levels to assess the sustainability of this positive trend.

In a pivotal development, IMUNON has commenced dosing the first patient in its Phase 3 OVATION 3 clinical trial, aimed at investigating the efficacy and safety of its lead candidate, IMNN-001, for women diagnosed with newly advanced ovarian cancer. Designed to evaluate the combination of IMNN-001 with standard neoadjuvant and adjuvant chemotherapy, this trial is positioned to potentially redefine treatment strategies for a condition with historically poor outcomes.

The first dose was administered by Dr. Melanie K. Bergman, a notable Gynecologic Oncologist, signaling a critical step in the clinical evaluation of IMNN-001. Dr. Bergman noted, “This innovative therapy could represent a transformative option for patients facing the difficult diagnosis of advanced ovarian cancer.” The primary endpoint of the trial focuses on overall survival, a vital metric given the challenges associated with advanced ovarian cancer, while secondary endpoints will further explore surgical and clinical outcomes.

Dr. Stacy Lindborg, President and CEO of IMUNON, expressed optimism about the IMNN-001 program, stating that the milestone of dosing the first patient underscores the company’s commitment to enhancing treatment outcomes for women globally. Through its proprietary TheraPlas® platform technology, IMUNON is paving the way for breakthroughs in immunotherapy not only for ovarian cancer but also across various disease landscapes.

Related news for (IMNN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.